Sacrosidase

Sacrosidase
Clinical data
Trade names	Sucraid
AHFS/Drugs.com	Monograph
Routes of; administration	Oral
ATC code	A16AB06 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	85897-35-4 ;
ChemSpider	none;
UNII	8A7F670F2Y;
ChEMBL	ChEMBL1201487 ;
	(what is this?) (verify)

Sacrosidase (trade name Sucraid) is a medication used to replace sucrase in people lacking this enzyme.^[1] It is available as an oral solution. Sucraid is approved by the U.S. Food and Drug Administration (FDA) for the therapy of the genetically determined sucrase deficiency that is part of the Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase assists in the breakdown of sugar/sucrose into simpler forms and is useful for the relief of gastrointestinal symptoms that are associated with CSID.

References

^ Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J (1999). "Sacrosidase therapy for congenital sucrase-isomaltase deficiency". J. Pediatr. Gastroenterol. Nutr. 28 (2): 137–142. doi:10.1097/00005176-199902000-00008. PMID 9932843.

External links

Sucraid Oral Solution helps relieve the gastrointestinal symptoms that are associated with CSID (Congenital Sucrase-Isomaltase deficiency).

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[pmid9932843-1] Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J (1999). "Sacrosidase therapy for congenital sucrase-isomaltase deficiency". J. Pediatr. Gastroenterol. Nutr. 28 (2): 137–142. doi:10.1097/00005176-199902000-00008. PMID 9932843.

[1]